SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Update

SAB Biotherapeutics, Inc. (NASDAQ:SABS) was the recipient of a significant drop in short interest in July. As of July 15th, there was short interest totalling 26,400 shares, a drop of 17.0% from the June 30th total of 31,800 shares. Based on an average daily volume of 16,600 shares, the days-to-cover ratio is currently 1.6 days. Approximately 0.4% of the shares of the stock are sold short.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in SABS. First PREMIER Bank purchased a new position in SAB Biotherapeutics during the second quarter worth $60,000. Commodore Capital LP purchased a new stake in shares of SAB Biotherapeutics in the fourth quarter valued at $1,259,000. BVF Inc. IL bought a new stake in shares of SAB Biotherapeutics in the 4th quarter worth about $6,310,000. Finally, RTW Investments LP purchased a new position in shares of SAB Biotherapeutics during the 4th quarter worth about $6,310,000. Institutional investors own 7.82% of the company’s stock.

Analyst Ratings Changes

SABS has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $6.00 price objective on shares of SAB Biotherapeutics in a research report on Tuesday, May 21st. Chardan Capital reiterated a “buy” rating and issued a $25.00 price target on shares of SAB Biotherapeutics in a research note on Tuesday, May 21st. Finally, Brookline Capital Management initiated coverage on shares of SAB Biotherapeutics in a report on Friday, June 7th. They set a “buy” rating and a $8.00 price objective for the company.

SAB Biotherapeutics Trading Up 2.5 %

Shares of SABS traded up $0.07 during mid-day trading on Monday, hitting $2.87. 10,158 shares of the stock were exchanged, compared to its average volume of 15,734. The firm has a 50-day moving average of $2.90 and a two-hundred day moving average of $4.24. SAB Biotherapeutics has a 52-week low of $2.36 and a 52-week high of $10.50. The company has a quick ratio of 5.65, a current ratio of 5.65 and a debt-to-equity ratio of 0.06.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings results on Monday, May 20th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.44. SAB Biotherapeutics had a negative net margin of 1,531.26% and a negative return on equity of 109.90%. The company had revenue of $0.95 million for the quarter. Analysts forecast that SAB Biotherapeutics will post -4.08 EPS for the current fiscal year.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.